Skip to main content
Premium Trial:

Request an Annual Quote

Invivoscribe Claims Win in FLT3 Patent Case

NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.

The San Diego-based firm said that the German District court in Munich found MLL Muenchner Leukaemielabor GmbH Laboratories guilty of infringing a patent held by Takara Bio and licensed exclusively to Invivoscribe. It also noted that the court declined to stay enforcement of its decision.

The patent, EP 959 132 B1, covers testing for internal tandem duplication mutations in the juxtamembrane region of FLT3. The presence of such mutations is associated with poor prognosis in acute myeloid leukemia patients.

Invivoscribe, which conducts testing in its labs in San Diego and in Germany, said the patents cover testing whether it is done by sequencing, by analysis of length, or by any other method.

Invivoscribe signed an expanded licensing deal with Takara Bio this past December covering FLT3 testing.